German vaccine developer BioNTech mentioned on Monday it was engaged on therapies to remedy most cancers because it reported income of €17.3 billion ($18.6 billion) for 2022 from its headquarters within the western metropolis of Mainz.
The firm, which gained worldwide renown for growing a vaccine towards Covid-19 primarily based on its novel mRNA (messenger ribonucleic acid) expertise, mentioned the determine was down from the virtually €19 billion recorded in 2021.
Net income got here in at €9.4 billion, down from €10.3 billion posted in 2021.
Looking forward, the corporate predicted turnover of round €5 billion from its Covid-19 vaccine over 2023.
During 2021, BioNTech and its US associate Pfizer provided greater than 2.6 billion doses of the vaccine. That determine fell to round 2 billion final yr.
Apart from vaccines towards the coronavirus, BioNTech is growing approaches in immunotherapy primarily based on mRNA to fight infectious and autoimmune ailments, in addition to most cancers.
It plans to arrange a advertising and marketing group within the United States, the European Union and different areas this yr and subsequent for future merchandise in treating most cancers.
Total funding in analysis and growth this yr is predicted to be between €2.4 billion and €2.6 billion.
Profits can even be utilized in a share buyback programme, with BioNTech looking for permission for as much as half a billion euros as much as the top of this yr.
Source: www.anews.com.tr
